189 related articles for article (PubMed ID: 11969046)
1. [Classification, favorable characteristics, prevention and treatment of adverse side-effects associated with Bacillus Calmette-Guerin in the treatment of superficial bladder cancer].
Saint F; Salomon L; Quintela R; Cicco A; Abbou CC; Chopin DK
Ann Urol (Paris); 2002 Mar; 36(2):120-31. PubMed ID: 11969046
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer.
Saint F; Irani J; Patard JJ; Salomon L; Hoznek A; Zammattio S; Debois H; Abbou CC; Chopin DK
Urology; 2001 May; 57(5):883-8. PubMed ID: 11337287
[TBL] [Abstract][Full Text] [Related]
3. [Urinary leukocytes as a new prognostic marker of therapeutic response and of adverse effects associated with the maintenance treatment with endovesical BCG, for the prophylaxis of superficial bladder tumors].
Saint F; Irani J; Salomon L; Legrand P; Abbou CC; Chopin D
Prog Urol; 2001 Dec; 11(6):1242-50. PubMed ID: 11859659
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy with intravesical bacillus Calmette-Guerin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer.
Muto S; Nakajima A; Horiuchi A; Inoue M; China T; Saito K; Isotani S; Hisasue S; Yamaguchi R; Ide H; Horie S
Jpn J Clin Oncol; 2013 Mar; 43(3):305-13. PubMed ID: 23303841
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
6. [ImmuCyst intravesical (freeze-dried preparation made from the connaught strain of Bacillus Calmette Guérin) for the treatment of superficial bladder cancer and carcinoma in situ of urinary bladder].
Tsukagoshi S
Gan To Kagaku Ryoho; 2003 Jul; 30(7):1027-38. PubMed ID: 12894724
[TBL] [Abstract][Full Text] [Related]
7. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
[TBL] [Abstract][Full Text] [Related]
8. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A
Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120
[TBL] [Abstract][Full Text] [Related]
9. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
[TBL] [Abstract][Full Text] [Related]
10. Bladder and penile lesions with inguinal adenopathy after intravesical Bacillus Calmette-Guerin (BCG) treatment.
Yates J; Stein B
Urology; 2007 Dec; 70(6):1223.e15-7. PubMed ID: 18158061
[TBL] [Abstract][Full Text] [Related]
11. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911.
Vegt PD; van der Meijden AP; Sylvester R; Brausi M; Höltl W; de Balincourt C
J Urol; 1997 Apr; 157(4):1246-9. PubMed ID: 9120912
[TBL] [Abstract][Full Text] [Related]
12. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy.
Ozbakkaloglu B; Tünger O; Sürücüoglu S; Lekili M; Kandiloglu AR
Int Urol Nephrol; 1999; 31(1):49-53. PubMed ID: 10408303
[TBL] [Abstract][Full Text] [Related]
13. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
14. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin in superficial bladder cancer: consensus and controversies.
Vegt PD; Debruyne FM; van der Meijden AP
Eur Urol; 1995; 27(2):89-95. PubMed ID: 7744164
[TBL] [Abstract][Full Text] [Related]
16. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials.
Chen S; Zhang N; Shao J; Wang X
Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363
[TBL] [Abstract][Full Text] [Related]
17. Bacillus Calmette-Guerin (BCG) balanitis as a complication of intravesical BCG immunotherapy: a case report.
Erol A; Ozgür S; Tahtali N; Akbay E; Dalva I; Cetin S
Int Urol Nephrol; 1995; 27(3):307-10. PubMed ID: 7591595
[No Abstract] [Full Text] [Related]
18. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence.
Irie A; Uchida T; Yamashita H; Matsumoto K; Satoh T; Koh H; Shimura S; Iwamura M; Baba S
Int J Urol; 2003 Apr; 10(4):183-9. PubMed ID: 12657096
[TBL] [Abstract][Full Text] [Related]
19. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
Witjes JA; vd Meijden AP; Debruyne FM
Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
[TBL] [Abstract][Full Text] [Related]
20. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
